Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) on Friday, soared 7.96% from the previous trading day, before settling in for the closing price of $1.13. Within the past 52 weeks, BCLI’s price has moved between $0.72 and $8.09.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company achieved an average annual earnings per share of 30.74%. With a float of $6.17 million, this company’s outstanding shares have now reached $7.91 million.
The firm has a total of 27 workers. Let’s measure their productivity. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Brainstorm Cell Therapeutics, Inc (BCLI) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Brainstorm Cell Therapeutics, Inc is 22.32%, while institutional ownership is 12.89%. The most recent insider transaction that took place on Oct 01 ’24, was worth 6,292. In this transaction President & CEO of this company bought 1,836 shares at a rate of $3.43, taking the stock ownership to the 80,960 shares. Before that another transaction happened on Sep 30 ’24, when Company’s President & CEO bought 22,000 for $0.23, making the entire transaction worth $5,016. This insider now owns 1,186,865 shares in total.
Brainstorm Cell Therapeutics, Inc (BCLI) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.74% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.48% during the next five years compared to 32.00% growth over the previous five years of trading.
Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) Trading Performance Indicators
Brainstorm Cell Therapeutics, Inc (BCLI) is currently performing well based on its current performance indicators. A quick ratio of 0.21 was reported for the most recent quarter.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.98, a number that is poised to hit -0.37 in the next quarter and is forecasted to reach -0.93 in one year’s time.
Technical Analysis of Brainstorm Cell Therapeutics, Inc (BCLI)
Analysing the last 5-days average volume posted by the [Brainstorm Cell Therapeutics, Inc, BCLI], we can find that recorded value of 0.37 million was lower than the volume posted last year of 0.75 million. As of the previous 9 days, the stock’s Stochastic %D was 71.21%. Additionally, its Average True Range was 0.13.
During the past 100 days, Brainstorm Cell Therapeutics, Inc’s (BCLI) raw stochastic average was set at 30.91%, which indicates a significant increase from 23.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 70.16% in the past 14 days, which was lower than the 92.35% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.1075, while its 200-day Moving Average is $1.9910. Now, the first resistance to watch is $1.2533. This is followed by the second major resistance level at $1.2866. The third major resistance level sits at $1.3532. If the price goes on to break the first support level at $1.1534, it is likely to go to the next support level at $1.0868. Now, if the price goes above the second support level, the third support stands at $1.0535.
Brainstorm Cell Therapeutics, Inc (NASDAQ: BCLI) Key Stats
Market capitalization of the company is 9.69 million based on 7,939K outstanding shares. Right now, sales total 0 K and income totals -11,620 K. The company made 0 K in profit during its latest quarter, and -2,860 K in sales during its previous quarter.
